Format

Send to

Choose Destination
Breast Cancer Res Treat. 2016 Jun;157(2):203-210. doi: 10.1007/s10549-016-3827-7. Epub 2016 May 13.

Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.

Author information

1
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 1441 Moursund St., Houston, TX, 77030, USA.
2
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, 1441 Moursund St., Houston, TX, 77030, USA. mtrivedi@uh.edu.
3
Lester and Sue Smith Breast Cancer, Baylor College of Medicine, Houston, TX, USA. mtrivedi@uh.edu.
4
Lester and Sue Smith Breast Cancer, Baylor College of Medicine, Houston, TX, USA.

Abstract

Atrophic vaginitis represents a major barrier to compliance with aromatase inhibitor (AI) therapy in breast cancer (BC) survivors. While local estrogen therapy is effective for postmenopausal vaginal dryness, the efficacy of such therapies has not been evaluated systematically in hormone receptor-positive (HR+) BC patients on AI therapy. Furthermore, the potential risk of breast cancer recurrence with vaginal estrogen therapy represents a long-term safety concern for the patients with HR + BC. Unfortunately, there is no standardized assay to measure very low concentrations of estradiol (E2) in these women being treated with AI therapy. This makes it difficult to evaluate even indirectly the potential risk of BC recurrence with vaginal estrogen therapy in HR + BC patients on AI therapy. In this review, we describe available assays to measure very low concentrations of E2, discuss the Food and Drug Administration-approved vaginal estrogen products on the market, and summarize published and ongoing clinical trials evaluating the safety and efficacy of vaginal estrogen in HR + BC patients on AI therapy. In the absence of any randomized controlled clinical trials, this review serves as a summary of available clinical data and ongoing studies to aid clinicians in selecting the best available option for their patients.

KEYWORDS:

Aromatase inhibitor; Breast cancer; Hormone receptor; Vaginal atrophy; Vaginal estradiol; Vaginal estriol; Vaginal estrogen; Vaginal symptoms

PMID:
27178335
DOI:
10.1007/s10549-016-3827-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center